You just read:

Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego

News provided by

Eiger BioPharmaceuticals, Inc.

Jun 12, 2017, 08:00 ET